18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting

<b>Background/Objectives:</b> The global increase in the incidence of malignant melanoma, without significant changes in the mortality rate, may be influenced by the changes in the diagnostic approach and criteria, and the impact of innovative therapies on the survival of patients. Advan...

Full description

Saved in:
Bibliographic Details
Main Authors: Silvija Lucic, Milena Spirovski, Borislava Nikolin, Dragana Stojanovic, Andrea Peter, Branislava Gajic, Vanja Cimbaljevic, Milos A. Lucic
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/15/12/1560
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849432538620100608
author Silvija Lucic
Milena Spirovski
Borislava Nikolin
Dragana Stojanovic
Andrea Peter
Branislava Gajic
Vanja Cimbaljevic
Milos A. Lucic
author_facet Silvija Lucic
Milena Spirovski
Borislava Nikolin
Dragana Stojanovic
Andrea Peter
Branislava Gajic
Vanja Cimbaljevic
Milos A. Lucic
author_sort Silvija Lucic
collection DOAJ
description <b>Background/Objectives:</b> The global increase in the incidence of malignant melanoma, without significant changes in the mortality rate, may be influenced by the changes in the diagnostic approach and criteria, and the impact of innovative therapies on the survival of patients. Advances in treatment options, influencing prolonged survival, are bringing up a strong need for close surveillance of melanoma patients. In this observational, retrospective, and single-center study, we determined the impact of 18F-FDG PET/CT diagnostics on the outcomes and survival of malignant melanoma patients at different stages from an extensive and unselected group in a real-life clinical management setting. <b>Methods:</b> A total number of 189 malignant melanoma patients who underwent 18F-FDG PET/CT examination in the course of the treatment at one university oncology institute during the period from January 2010 to December 2024 were included in the study, and the multifactorial impact on the outcome and survival of malignant melanoma patients was observed in regard to the differences resulting from the therapeutic approaches and the introduction of new therapeutic options and drugs. <b>Results & Conclusions:</b> Our results indicate that 18F-FDG PET/CT is a sensitive imaging tool for the detection of predominantly distant metastases in malignant melanoma patients belonging to an extensive and unselected population in a real-world clinical setting, not only at advanced melanoma stages but also at early stages of high-risk patients’ surveillance. Follow-up appears to be of substantial importance for patients at advanced stages, but also for patients at early stages of disease, in particular in the presence of a strong clinical suspicion. Immunotherapy and combined therapy are improving overall survival in melanoma patients in real-world circumstances and equivalent clinical surroundings.
format Article
id doaj-art-c519b56c019c47c79e344b48151faf0e
institution Kabale University
issn 2075-4418
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj-art-c519b56c019c47c79e344b48151faf0e2025-08-20T03:27:21ZengMDPI AGDiagnostics2075-44182025-06-011512156010.3390/diagnostics1512156018F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World SettingSilvija Lucic0Milena Spirovski1Borislava Nikolin2Dragana Stojanovic3Andrea Peter4Branislava Gajic5Vanja Cimbaljevic6Milos A. Lucic7Medical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, SerbiaMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, SerbiaMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, SerbiaOncology Institute of Vojvodina, 21000 Novi Sad, SerbiaMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, SerbiaMedical Faculty, University of Novi Sad, Clinic of Dermatovenereology Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, SerbiaOncology Institute of Vojvodina, 21000 Novi Sad, SerbiaMedical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia<b>Background/Objectives:</b> The global increase in the incidence of malignant melanoma, without significant changes in the mortality rate, may be influenced by the changes in the diagnostic approach and criteria, and the impact of innovative therapies on the survival of patients. Advances in treatment options, influencing prolonged survival, are bringing up a strong need for close surveillance of melanoma patients. In this observational, retrospective, and single-center study, we determined the impact of 18F-FDG PET/CT diagnostics on the outcomes and survival of malignant melanoma patients at different stages from an extensive and unselected group in a real-life clinical management setting. <b>Methods:</b> A total number of 189 malignant melanoma patients who underwent 18F-FDG PET/CT examination in the course of the treatment at one university oncology institute during the period from January 2010 to December 2024 were included in the study, and the multifactorial impact on the outcome and survival of malignant melanoma patients was observed in regard to the differences resulting from the therapeutic approaches and the introduction of new therapeutic options and drugs. <b>Results & Conclusions:</b> Our results indicate that 18F-FDG PET/CT is a sensitive imaging tool for the detection of predominantly distant metastases in malignant melanoma patients belonging to an extensive and unselected population in a real-world clinical setting, not only at advanced melanoma stages but also at early stages of high-risk patients’ surveillance. Follow-up appears to be of substantial importance for patients at advanced stages, but also for patients at early stages of disease, in particular in the presence of a strong clinical suspicion. Immunotherapy and combined therapy are improving overall survival in melanoma patients in real-world circumstances and equivalent clinical surroundings.https://www.mdpi.com/2075-4418/15/12/1560malignant melanomaearly stagesadvanced stages18F-FDG PET/CTsurvival
spellingShingle Silvija Lucic
Milena Spirovski
Borislava Nikolin
Dragana Stojanovic
Andrea Peter
Branislava Gajic
Vanja Cimbaljevic
Milos A. Lucic
18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting
Diagnostics
malignant melanoma
early stages
advanced stages
18F-FDG PET/CT
survival
title 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting
title_full 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting
title_fullStr 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting
title_full_unstemmed 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting
title_short 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting
title_sort 18f fdg pet ct impact on malignant melanoma patients undergoing staging and restaging a single university center experience in a real world setting
topic malignant melanoma
early stages
advanced stages
18F-FDG PET/CT
survival
url https://www.mdpi.com/2075-4418/15/12/1560
work_keys_str_mv AT silvijalucic 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT milenaspirovski 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT borislavanikolin 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT draganastojanovic 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT andreapeter 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT branislavagajic 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT vanjacimbaljevic 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting
AT milosalucic 18ffdgpetctimpactonmalignantmelanomapatientsundergoingstagingandrestagingasingleuniversitycenterexperienceinarealworldsetting